A previous diagnosis of Crohn disease may aid in the diagnosis of MCD, although, as previously mentioned, MCD may present without classical gastrointestinal manifestations of Crohn disease.
Metastatic Crohn disease is a rare cutaneous manifestation of Crohn disease.
Metastatic cutaneous Crohn disease of the face: a case report and review of the literature.
Evidence of publication bias was found in only a single metaanalysis, the analysis for Gly908Arg in individuals with familial Crohn disease.
The present metaanalysis of79 hospital- and population-based case-control studies including 18 727 cases and 17 102 controls for Crohn disease provides the most comprehensive assessment thus far for the association between NOD2 genetic variants and the risk of Crohn disease.
In accordance with results from 2 previous case-control studies (14, 15), we detected no evidence for differences in risk estimates for NOD2 genetic variants for Crohn disease in individuals from northern Europe vs southern Europe.
Third, for the first time in a metaanalysis, we compared the magnitude of the odds ratios for Crohn disease for heterozygosity and homozygosity for each of the 3 NOD2 genetic variants.
Fourth, when we combined all genotypes in the present study (including 79 studies), the risk of Crohn disease was 2-fold higher for simple heterozygotes and 7-fold to 9-fold higher for compound heterozygotes and homozygotes.
Because all of the included studies were case-control studies, the results of these metaanalyses present effect sizes for people already with a diagnosis for the disease studied, but that fact does not necessarily imply that sizes of the effects on the risk of Crohn disease found for these genotypes will be similar to those in the general population.
Recent genome-wide association studies have identified >30 other genetic variants associated with Crohn disease (26); however, many of these new variants have smaller effects on the risk of Crohn disease (26) than those reported for NOD2 (13).